文献速递泌尿男性生殖肿瘤

血清素经表观遗传重编程调控神经内分泌前列腺癌谱系可塑性

Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming.
PubMed 文献 · Cancer Discov · 2026-01-01

本研究揭示神经内分泌前列腺癌(NEPC)内源性血清素轴驱动谱系承诺与进展。NEPC通过AADC合成血清素并经SLC6A4再摄取,胞内高血清素促进H3K4me3Q5组蛋白血清素化,重塑染色质景观驱动神经内分泌分化并抑制雄激素受体信号。FDA批准的DDC抑制剂卡比多巴可显著抑制肿瘤生长并延长生存。

要点

  • NEPC内源性血清素轴通过AADC合成和SLC6A4再摄取驱动谱系可塑性。
  • 胞内血清素促进H3K4me3Q5组蛋白血清素化,重塑染色质驱动神经内分泌分化。
  • 卡比多巴抑制血清素合成,在GEMM和PDX模型中抑制肿瘤生长并延长生存。

核心结论

  • NEPC存在肿瘤内在血清素轴驱动谱系承诺和进展,组蛋白血清素化是可靶向的治疗脆弱点。

研究设计与样本

  • 本研究采用基因工程小鼠模型和患者来源异种移植模型,结合机制探索与药物干预实验。

主要发现

  • NEPC通过AADC(由DDC编码)内源性合成血清素,并经SLC6A4转运体再摄取。
  • 高胞内血清素促进H3K4me3Q5组蛋白血清素化,重构H3K4me3染色质景观及下游基因表达,驱动神经内分泌分化并关联雄激素受体信号抑制。
  • FDA批准的DDC抑制剂卡比多巴药理抑制血清素合成,在基因工程和患者来源异种移植模型中均显著损害肿瘤生长并延长生存。

临床怎么用

  • 卡比多巴作为FDA批准的DDC抑制剂,在NEPC模型中显示可抑制肿瘤生长并延长生存,提示组蛋白血清素化可作为治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Neuroendocrine prostate cancer (NEPC) is an aggressive, therapy-resistant subtype of prostate cancer characterized by lineage plasticity. Although metabolic and signaling molecules are increasingly recognized as modulators of tumor progression, their role in cell fate transition remains unclear. NE (neuroendocrine) tumors produce and accumulate serotonin, a neurotransmitter that regulates diverse physiologic processes. In this study, we identify a tumor-intrinsic serotonin axis as a key driver of NEPC lineage commitment and progression. NEPC endogenously synthesizes serotonin via aromatic L-amino acid decarboxylase (AADC; encoded by DDC) and reuptakes it through the transporter SLC6A4. Mechanistically, high levels of intracellular serotonin promote histone serotonylation at H3K4me3Q5, reconfiguring the H3K4me3 chromatin landscape and downstream gene expression, which drives NE differentiation and is associated with suppressed androgen receptor signaling. Pharmacologic inhibition of serotonin synthesis using the FDA-approved DDC inhibitor carbidopa significantly impairs tumor growth and prolongs survival in both genetically engineered and patient-derived xenograft models, highlighting histone serotonylation as a druggable vulnerability in NEPC. SIGNIFICANCE: Collectively, our findings uncover an epigenetically embedded, serotonin-driven lineage program in NEPC, coupling tumor-intrinsic serotonin metabolism with tumor cell fate control, and identify histone serotonylation as a tractable therapeutic vulnerability in lineage-plastic prostate cancer.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Ji Y, Ju CW, Chen L, et al. Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. Cancer Discov. 2026. PMID: 41416996. doi:10.1158/2159-8290.CD-25-0974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。